首页> 美国卫生研究院文献>Advanced Science >Penetrable Nanoplatform for Cold Tumor Immune Microenvironment Reeducation
【2h】

Penetrable Nanoplatform for Cold Tumor Immune Microenvironment Reeducation

机译:用于冷肿瘤免疫微环境的可渗透纳米片

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lack of tumor‐infiltration lymphocytes (TILs) and resistances by overexpressed immunosuppressive cells (principally, myeloid‐derived suppressor cells (MDSCs)) in tumor milieu are two major challenges hindering the effectiveness of immunotherapy for “immune‐cold” tumors. In addition, the natural physical barrier existing in solid cancer also limits deeper delivery of drugs. Here, a tumor‐targeting and light‐responsive‐penetrable nanoplatform (Apt/PDGs^s@pMOF) is developed to elicit intratumoral infiltration of cytotoxic T cells (CTLs) and reeducate immunosuppressive microenvironment simultaneously. In particular, porphyrinic metal–organic framework (pMOF)–based photodynamic therapy (PDT) induces tumor immunogenic cell death (ICD) to promote CTLs intratumoral infiltration and hot “immune‐cold” tumor. Upon being triggered by PDT, the nearly 10 nm adsorbed drug‐loaded dendrimer de‐shields from the nanoplatform and spreads into the deeper tumor, eliminating MDSCs and reversing immunosuppression, eventually reinforcing immune response. Meanwhile, the designed nanoplatform also has a systemic MDSC inhibition effect and moderate improvement of overall antitumor immune responses, resulting in effective suppression of distal tumors within less significant immune‐related adverse effects (irAEs) induced.
机译:患有过表达免疫抑制细胞的肿瘤浸润淋巴细胞(TIL)和肿瘤内肿瘤的抗性(主要是,肿瘤Milieu中的骨髓源性抑制细胞(MDSCS))是阻碍“免疫感冒”肿瘤的免疫疗法有效性的两个主要挑战。此外,固体癌症中存在的天然物理屏障还限制了更深的药物递送。这里,开发了肿瘤靶向和抗响应性渗透纳米片(APT / PDGS ^ PMOF)以同时引发细胞毒性T细胞(CTL)的血液渗透并同时重新核肉免疫抑制微环境。特别地,卟啉金属 - 有机骨架(PMOF)基础的光动力治疗(PDT)诱导肿瘤免疫原性细胞死亡(ICD),以促进CTL危险型浸润和热的“免疫感冒”肿瘤。通过PDT触发,从纳米载体的近10nm吸附的药物装载的树枝状块脱屏,并扩散到更深的肿瘤中,消除MDSC和逆转免疫抑制,最终增强免疫应答。同时,设计的纳米型纳米型抑制作用和整体抗肿瘤免疫应答的全身抑制作用和适度的改善,导致有效抑制远端肿瘤,在不太显着的免疫相关的不良反应(伊拉氏)中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号